GlassScriptPhysician profile
Trysari Sudiro
NPI 1396432399
$2,242.05
in general payments reported to CMS, 2019-2025
26 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $670 · 2024: $337 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.06 |
| Education | $377.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $396.62 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $325.95 | 2023-2025 | Tagrisso, Enhertu |
| Janssen Biotech, INC. | $311.88 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $119.92 | 2023 | |
| Tempus Ai, INC | $118.14 | 2024 | |
| Seagen INC. | $99.99 | 2023 | |
| Daiichi Sankyo INC. | $99.32 | 2025 | Enhertu, Datroway |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Beone Medicines USA, INC. | $98.78 | 2025 | Brukinsa |
| Incyte Corporation | $80.36 | 2025 | Jakafi, Niktimvo |
| Ipsen Biopharmaceuticals, INC | $79.84 | 2025 | Onivyde, Somatuline Depot |
| Abbvie INC. | $54.29 | 2024 | |
| Lilly USA, LLC | $50.32 | 2024-2025 | Verzenio, Jaypirca |
| Chiesi USA, INC. | $34.42 | 2025 | Ferriprox |
| Dendreon Pharmaceuticals LLC | $31.90 | 2025 | Provenge |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $30.13 | 2025 | |
| Genentech USA, INC. | $29.58 | 2025 | Polivy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.32 | 2023 | |
| Coherus Oncology, INC. | $21.90 | 2025 | Loqtorzi |
| Genmab U.S., INC. | $21.66 | 2024 | Epkinly |
| Paratek Pharmaceuticals, INC. | $21.31 | 2024 | Nuzyra |
| Caris Mpi, INC. | $20.21 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $17.50 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $17.10 | 2024 | Sancuso |
| Amgen INC. | $16.76 | 2023 | Xgeva, Vectibix, Nplate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trysari Sudiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.